#4499
Impact of early molecular tumour board inclusion on treatment outcomes in neuroendocrine neoplasms: A retrospective double-centre study
Introduction:
The treatment of neuroendocrine neoplasms (NENs) is particularly challenging due to the limited availability of standard therapies. While personalised approaches are revolutionising many areas of oncology, their progress in the field of NENs has been comparatively slower. The integration of molecular tumour boards (MTBs) into clinical practice represents a major advance in oncology, even for rare entities such as NENs.
Conference:
Presenting Author:
Klaas L
Authors:
Barsch M,
Graessel L,
Metzger P,
Klaas L,
Schulz L,
Keywords:
Neuroendocrine neoplasm,
Molecular Tumour Board,
personalised medicine,
precision oncology,
targeted therapy,
#3380
Dose selection for paltusotine, a once daily oral nonpeptide, somatostatin receptor 2 ligand, for the treatment of patients with Carcinoid Syndrome (CS)
Introduction:
Long-acting somatostatin receptor ligands (LA-SRLs) are first line therapy for neuroendocrine tumor (NET) syndromes including acromegaly and the carcinoid syndrome (CS). In acromegaly, two phase 2 studies (NCT 03789656 and 03792555) suggested that patients injected with SRLs can switch to once daily orally bioavailable paltusotine (CRN00808), a nonpeptide, small molecule, somatostatin type 2 (SST2) receptor ligand (SRL), while maintaining stable serum IGF-1 levels. However, CS patients may require higher doses of an orally administered drug due to maldigestion commonly associated with the syndrome or its treatment and the pharmacokinetics (clearance and volume of distribution) of paltusotine may differ between CS and acromegaly because of differences in metabolic capacity of the liver and body composition.
Conference:
Presenting Author:
Authors:
Lagast H,
Madan A,
Metz D,
Luo R,
Struthers S,
Keywords:
neuroendocrine tumor,
carcinoid syndrome,
paltusotine,
somatostatine receptor ligand,
dose-response,
exposure-response,
#2750
Progression-Free Survival and Clinical Outcomes with Long-Term Use of Telotristat Ethyl in US Clinical Practice
Introduction:
Treatment of advanced neuroendocrine tumors aims to relieve symptoms and suppress tumor growth. Primary findings from the TELEACE study suggested telotristat ethyl (TE) may reduce tumor size and impact tumor growth.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Metz D
Authors:
Metz D,
Liu E,
Joish V,
Huynh L,
Cheng M,
Keywords:
neuroendocrine tumor,
carcinoid syndrome,
telotristat ethyl,
serotonin,
tumor growth,
progression-free survival,
